![]() |
New to the Huntington's Disease Lighthouse? |
||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HD Lighthouse Contributing Editor's Comment: In 1997, researchers discovered that the mutant huntingtin protein bunches up to form nuclear inclusions (NIs) in the cells of HD mice [1]. Since that time, Huntington's has been classified as a disease of aberrant protein accumulation. Other diseases in this class include Alzheimer's, Parkinson's, prion (mad-cow) disease, and type II diabetes.
However, recent studies have found that the accumulated proteins in these different diseases - the proteins forming NIs, or amyloid or aggregates - have still more in common, namely their shape [2]. This common shape is due to a pattern of molecular hydrogen bonding that forms between strands of the aberrant proteins, producing so-called beta (β) sheets. Beta sheets consist of amino acid sequences that are adjacent and in parallel, in such a way that hydrogen bonds form between the two strands. It has been known or suspected for some time that HD and other aggregates are rich in this structure known as beta sheets. Linus Pauling and Robert Corey first postulated the existence of beta sheets in 1951 [3], as one basic protein structure. Dr. Max Perutz, the Nobel prize winning father of X-ray crystallography, predicted that polyglutamine strands specifically would zip up due to their hydrogen bonding into a compact structure held together by a polar zipper [4] to form the beta sheets. (Polyglutamine strands are protein pieces that consist of CAG repeats, exactly like the repeats seen in Huntington's; Huntington's is a polyglutamine disease.) While the protein fragments that make up aggregates in the different diseases have different sequences of amino acids, the backbones of these different proteins are identical, and the hydrogen bonding of the backbones (as well as bonding between the amino acid residues) produces the aggregations. When full-length nuclear inclusions of the huntingtin protein were first discovered in HD mice [1], they were believed to be the critical pathological trigger of the disease - the "smoking gun." However, later research found conflicting evidence about the exact role of these inclusions - for example, a 1999 paper by Kuemmerle and colleagues found that NIs were not associated with neuronal death in HD [5] - and controversy ensued. The consensus today is that it is not the largest inclusions that are most toxic to neurons. Apparently, smaller inclusions of interconnected proteins (oligomers, or mid-sized molecules) represent a mid-stage in the development of the largest inclusions, and these oligomers seem to be a major toxic agent, according to research.
A new paper by Dr. Charles Glabe of the University of California, Irvine, (abstract below) reviews the NI/aggregation/amyloid literature and makes an intriguing case that the common structure of these aggregations may be a disease mechanism that different diseases have in common. Another important feature of aggregate formation is that it seems to happen reasonably early in disease processes, and, for a variety of diseases, including HD, it may be an upstream event that leads to many downstream toxic cellular processes. More specifically, there is evidence to believe that, once the various amyloid oligomers are formed in the various diseases, they punch holes, or pores, in the cell membrane. This assault in turn may make the cell more permeable, leading to the uncontrolled influx of calcium into the cell, a process that itself may then destabilize many other essential cell processes. The idea that such pore formation leads to many downstream pathological processes is called "the channel hypothesis." Dr. Glabe observes that the increase in intracellular calcium may be the proximate initiator of several pathogenic pathways, including oxidative damage, altered signaling pathways, mitochondrial dysfunction, and cell death. To the degree Dr. Glabe's hypothesis is true, then modifying the upstream events that lead to channel formation might eliminate many damaging downstream cellular processes in HD and other protein aggregation diseases. That would be great news. Additionally, if the diseases share a common toxic mechanism, that means scientists focusing on these different diseases are actually working on different instances of the same puzzle. If this commonality is borne out in further research, it could speed drug discovery for HD. We look forward to hearing much more about the channel hypothesis from pharmaceutical companies and academic scientists who will be searching for compounds to prevent channel formation in HD. References: 1. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997, Aug 8;90(3):537-48. 2. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003, Apr 18;300(5618):486-9. 3. Eisenberg, David. The discovery of the a-helix and b-sheet, the principal structural features of proteins. Proceedings of the National Academy of Sciences. 2003, Sept 30;100(20):11207-11210 (http://www.pnas.org/cgi/content/full/100/20/11207). 4. Perutz MF. Polar zippers: their role in human disease. Pharm Acta Helv. 1995, Mar;69(4):213-24. 5. Kuemmerle, S, Gutekunst, CA, Klein, AM, Li XJ, Li SH, Beal, MF, Hersch, SM, Ferrante, RJ. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol. 1999, Dec;46(6):842-9. Commentary by Malcolm Casale, Ph.D. and Ann Covalt, M.A.
Dr. Charles G. Glabe Common mechanisms of amyloid oligomer pathogenesis in degenerative diseaseCharles Glabe Tracked on the Lighthouse:
Source: Neurobiol Aging. 2006, Apr. 27(4):570-5.
|
Research focusing on the formation of aggregates caused by HD
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
Learn more about the clinical trial process, trials that have been conducted and those that are underway.
Research related to drugs and supplements that may delay onset and slow progression of Huntington's Disease.
Research focusing on gene therapy.
Research focusing on gene transcription.
General research related to HD
Research studying the genetics of Huntington's Disease
Research studying the Immune System and it's effect on the progression of HD
Research studying the brain tissue and research related to stem cells
26 Sep 2007
Press release for the BDNF neurogenesis study.
25 Aug 2007
Gene Expression Analysis and Extra-Mitochondrial Energy Metabolism
The HD protein causes a depletion in cellular energy but not through direct effects on the mitochondria, the cell's energy factory.
24 Aug 2007
RE1/NRSE Mediated Gene Transcription
Exciting research suggests that restoring the expression of the genes that the HD protein suppresses could be a major treatment.
20 Aug 2007
The Molecular Zip Code Research Yields a Drug Target
The molecular zip code research suggests that a kinase inhibitor could be a major treatment for Huntington
19 May 2007
D1 receptors and HD
Researchers generated a mouse which progressively lost Dopamine 1 receptor cells and got Huntington's Disease like symptoms.
1 Apr 2007
Copper in the HD brain
Researchers have discovered that excess copper plays a role in Huntington's Disease pathology.
13 Feb 2007
Molecular Zipcodes Provide Address for HD Protein
New findings based on new technology show that the HD protein is being misdirected within the cell. Small molecules are being developed which might place a 'molecular zip code' on the problem.
6 Feb 2007
NCAMs in the HD mice
Problems with NCAMs may explain cognitive and olfactory dysfunction in HD.
19 Dec 2006
Stem Cells and The Aging Brain
Stem cells are still present in the middle aged brain; they just aren't dividing.
8 Dec 2006
ReNeuron Files Application with FDA to Begin Phase I Study of Stem Cell Treatment for Stroke Patients.
A company currently doing stem cell research in animal models of HD, has filed an application with the FDA for permission to begin clinical trials of stem cell treatments for stroke victims.
All Updates for The Brain | |||||||||||||||||||||||||
| Disclaimer & Privacy
Policy | |
|